TVTXTravere Therapeutics, Inc.

Nasdaq travere.com


$ 8.91 $ -0.10 (-1.11 %)    

Tuesday, 20-Aug-2024 15:59:59 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 8.9
$ 9.01
$ 8.90 x 100
$ 8.92 x 300
$ 8.84 - $ 9.15
$ 5.12 - $ 15.39
522,727
na
689.75M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 02-20-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 10-27-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 07-29-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 02-24-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-01-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-04-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-11-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-travere-therapeutics-raises-price-target-to-20

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-20

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 barclays-maintains-overweight-on-travere-therapeutics-raises-price-target-to-14

Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

 piper-sandler-maintains-neutral-on-travere-therapeutics-raises-price-target-to-12

Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...

 wedbush-maintains-outperform-on-travere-therapeutics-raises-price-target-to-16

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from ...

 travere-therapeutics-q2-2024-adj-eps-065-beats-086-estimate-sales-52176m-beat-50169m-estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-travere-therapeutics-maintains-19-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $19 price tar...

 canaccord-genuity-maintains-buy-on-travere-therapeutics-raises-price-target-to-18

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target fr...

 travere-therapeutics-q1-2024-adj-eps-151-misses-099-estimate-sales-41374m-miss-42847m-estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-19

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 csl-vifor-and-travere-therapeutics-granted-european-commission-conditional-marketing-authorization-for-filspari-sparsentan-for-the-treatment-of-iga-nephropathy

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing autho...

 reported-earlier-travere-therapeutics-and-ccl-vifor-get-european-commission-approval-of-sparsentan-for-the-treatment-of-iga-nephropathy

https://ec.europa.eu/transparency/documents-register/detail?ref=C(2024)2719&lang=en 

 wedbush-reiterates-outperform-on-travere-therapeutics-maintains-13-price-target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $13 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION